ABEONA THERAPEUTICS INC (ABEO) Fundamental Analysis & Valuation

NASDAQ:ABEO • US00289Y2063

5.16 USD
+0.31 (+6.39%)
At close: Mar 9, 2026
5.2153 USD
+0.06 (+1.07%)
After Hours: 3/9/2026, 8:00:01 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This ABEO fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to ABEO. ABEO was compared to 519 industry peers in the Biotechnology industry. The financial health of ABEO is average, but there are quite some concerns on its profitability. ABEO is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

2

1. ABEO Profitability Analysis

1.1 Basic Checks

  • ABEO had negative earnings in the past year.
  • ABEO had a negative operating cash flow in the past year.
  • ABEO had negative earnings in each of the past 5 years.
  • In the past 5 years ABEO always reported negative operating cash flow.
ABEO Yearly Net Income VS EBIT VS OCF VS FCFABEO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

  • With an excellent Return On Assets value of 35.63%, ABEO belongs to the best of the industry, outperforming 98.46% of the companies in the same industry.
  • Looking at the Return On Equity, with a value of 48.09%, ABEO belongs to the top of the industry, outperforming 98.46% of the companies in the same industry.
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROIC N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ABEO Yearly ROA, ROE, ROICABEO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100 -200 -300

1.3 Margins

  • ABEO has a better Profit Margin (20587.50%) than 99.81% of its industry peers.
  • The Operating Margin and Gross Margin are not available for ABEO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) 20587.5%
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABEO Yearly Profit, Operating, Gross MarginsABEO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. ABEO Health Analysis

2.1 Basic Checks

  • ABEO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • ABEO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, ABEO has more shares outstanding
  • Compared to 1 year ago, ABEO has a worse debt to assets ratio.
ABEO Yearly Shares OutstandingABEO Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
ABEO Yearly Total Debt VS Total AssetsABEO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

  • Based on the Altman-Z score of -1.75, we must say that ABEO is in the distress zone and has some risk of bankruptcy.
  • With a Altman-Z score value of -1.75, ABEO perfoms like the industry average, outperforming 49.90% of the companies in the same industry.
  • ABEO has a Debt/Equity ratio of 0.06. This is a healthy value indicating a solid balance between debt and equity.
  • ABEO has a Debt to Equity ratio of 0.06. This is comparable to the rest of the industry: ABEO outperforms 40.66% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Altman-Z -1.75
ROIC/WACCN/A
WACC8.79%
ABEO Yearly LT Debt VS Equity VS FCFABEO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • ABEO has a Current Ratio of 9.74. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
  • ABEO's Current ratio of 9.74 is fine compared to the rest of the industry. ABEO outperforms 79.38% of its industry peers.
  • ABEO has a Quick Ratio of 9.53. This indicates that ABEO is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of ABEO (9.53) is better than 79.58% of its industry peers.
Industry RankSector Rank
Current Ratio 9.74
Quick Ratio 9.53
ABEO Yearly Current Assets VS Current LiabilitesABEO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. ABEO Growth Analysis

3.1 Past

  • ABEO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 57.38%, which is quite impressive.
  • The Revenue for ABEO has decreased by -100.00% in the past year. This is quite bad
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • ABEO is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 28.39% yearly.
  • ABEO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 412.56% yearly.
EPS Next Y173.18%
EPS Next 2Y40.11%
EPS Next 3Y37.35%
EPS Next 5Y28.39%
Revenue Next Year6533.33%
Revenue Next 2Y3247.96%
Revenue Next 3Y1168.37%
Revenue Next 5Y412.56%

3.3 Evolution

ABEO Yearly Revenue VS EstimatesABEO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ABEO Yearly EPS VS EstimatesABEO Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 -10 -20 -30

More info and screens

Find the best growth stocksShow best growing peers

1

4. ABEO Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABEO. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABEO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABEO Price Earnings VS Forward Price EarningsABEO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABEO Per share dataABEO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 3

4.3 Compensation for Growth

  • A more expensive valuation may be justified as ABEO's earnings are expected to grow with 37.35% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y40.11%
EPS Next 3Y37.35%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. ABEO Dividend Analysis

5.1 Amount

  • No dividends for ABEO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABEO Fundamentals: All Metrics, Ratios and Statistics

ABEONA THERAPEUTICS INC

NASDAQ:ABEO (3/9/2026, 8:00:01 PM)

After market: 5.2153 +0.06 (+1.07%)

5.16

+0.31 (+6.39%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12
Earnings (Next)03-17
Inst Owners69.99%
Inst Owner Change11.06%
Ins Owners7.05%
Ins Owner Change11.38%
Market Cap279.62M
Revenue(TTM)400.00K
Net Income(TTM)82.35M
Analysts86.67
Price Target21.06 (308.14%)
Short Float %29.69%
Short Ratio12.64
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)15.03%
Min EPS beat(2)-36.14%
Max EPS beat(2)66.19%
EPS beat(4)3
Avg EPS beat(4)31.61%
Min EPS beat(4)-36.14%
Max EPS beat(4)66.19%
EPS beat(8)4
Avg EPS beat(8)4.74%
EPS beat(12)7
Avg EPS beat(12)27.06%
EPS beat(16)9
Avg EPS beat(16)18.42%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)2.12%
EPS NQ rev (1m)-4.21%
EPS NQ rev (3m)-4.21%
EPS NY rev (1m)1.33%
EPS NY rev (3m)1.33%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 699.05
P/FCF N/A
P/OCF N/A
P/B 1.63
P/tB 1.63
EV/EBITDA N/A
EPS(TTM)-1.01
EYN/A
EPS(NY)-0.06
Fwd EYN/A
FCF(TTM)-1.52
FCFYN/A
OCF(TTM)-1.38
OCFYN/A
SpS0.01
BVpS3.16
TBVpS3.16
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA 35.63%
ROE 48.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) 20587.5%
GM N/A
FCFM N/A
ROA(3y)-70.3%
ROA(5y)-74.66%
ROE(3y)-224.16%
ROE(5y)-183.97%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0.06
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 476.46%
Cap/Sales 1857%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.74
Quick Ratio 9.53
Altman-Z -1.75
F-Score6
WACC8.79%
ROIC/WACCN/A
Cap/Depr(3y)46.91%
Cap/Depr(5y)59.52%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.38%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%84.13%
EPS Next Y173.18%
EPS Next 2Y40.11%
EPS Next 3Y37.35%
EPS Next 5Y28.39%
Revenue 1Y (TTM)-100%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year6533.33%
Revenue Next 2Y3247.96%
Revenue Next 3Y1168.37%
Revenue Next 5Y412.56%
EBIT growth 1Y-36.97%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-95.77%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-79.43%
OCF growth 3YN/A
OCF growth 5YN/A

ABEONA THERAPEUTICS INC / ABEO FAQ

Can you provide the ChartMill fundamental rating for ABEONA THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to ABEO.


Can you provide the valuation status for ABEONA THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to ABEONA THERAPEUTICS INC (ABEO). This can be considered as Overvalued.


How profitable is ABEONA THERAPEUTICS INC (ABEO) stock?

ABEONA THERAPEUTICS INC (ABEO) has a profitability rating of 2 / 10.